We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
+10.91%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$656M
AUM Growth
+$43.2M
Cap. Flow
-$10.7M
Cap. Flow %
-1.63%
Top 10 Hldgs %
31%
Holding
140
New
7
Increased
40
Reduced
26
Closed
13

Top Buys

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$7.77M
2
CNC icon
Centene
CNC
+$5.07M
3
LCI
Lannett Company, Inc.
LCI
+$4.41M
4
VTRS icon
Viatris
VTRS
+$4.34M
5
CVS icon
CVS Health
CVS
+$4.04M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$13.6M
2
RDY icon
Dr. Reddy's Laboratories
RDY
+$8.31M
3
KITE
Kite Pharma, Inc.
KITE
+$7.43M
4
THC icon
Tenet Healthcare
THC
+$3.82M
5
ABT icon
Abbott
ABT
+$3.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.1%
2 Financials 1.62%
3 Industrials 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHN
51
DELISTED
Achillion Pharmaceuticals
ACHN
$4.53M 0.69%
420,000
– –
LCI
52
DELISTED
Lannett Company, Inc.
LCI
$4.31M 0.66%
+26,870
New +$4.41M
BAX icon
53
Baxter International
BAX
$14.1B
$4.2M 0.64%
110,000
+60,000
+120% +$2.19M
ELV icon
54
Elevance Health
ELV
$84.8B
$4.18M 0.64%
30,000
– –
BMY icon
55
Bristol-Myers Squibb
BMY
$130B
$4.13M 0.63%
60,000
– –
HCA icon
56
HCA Healthcare
HCA
$88.7B
$4.06M 0.62%
60,000
+20,000
+50% +$1.4M
NBIX icon
57
Neurocrine Biosciences
NBIX
$16.4B
$3.68M 0.56%
65,000
– –
NKTR icon
58
Nektar Therapeutics
NKTR
$2.47B
$3.64M 0.55%
14,400
-1,600
-10% -$329K
CERN
59
DELISTED
Cerner Corp
CERN
$3.61M 0.55%
60,000
+5,000
+9% +$308K
PFE icon
60
Pfizer
PFE
$147B
$3.55M 0.54%
115,940
+26,350
+29% +$829K
AGIO icon
61
Agios Pharmaceuticals
AGIO
$1.89B
$3.51M 0.53%
54,000
– –
NVDQ
62
DELISTED
Novadaq Technologies Inc.
NVDQ
$3.19M 0.49%
250,000
– –
MRK icon
63
Merck
MRK
$317B
$3.17M 0.48%
62,880
– –
HOLX
64
DELISTED
Hologic
HOLX
$3.13M 0.48%
81,000
– –
MASI
65
DELISTED
Masimo
MASI
$3.11M 0.47%
75,000
– –
ARIA
66
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3.09M 0.47%
495,000
– –
SGEN
67
DELISTED
Seagen Inc. Common Stock
SGEN
$3.05M 0.47%
68,000
+20,000
+42% +$832K
MDVN
68
DELISTED
MEDIVATION, INC.
MDVN
$3.04M 0.46%
63,000
+10,400
+20% +$449K
VAR
69
DELISTED
Varian Medical Systems, Inc.
VAR
$2.99M 0.46%
42,194
– –
LLY icon
70
Eli Lilly
LLY
$1.04T
$2.95M 0.45%
35,000
– –
TMO icon
71
Thermo Fisher Scientific
TMO
$214B
$2.84M 0.43%
20,000
– –
NVAX icon
72
Novavax
NVAX
$1.27B
$2.73M 0.42%
16,250
– –
MGNX icon
73
MacroGenics
MGNX
$248M
$2.57M 0.39%
83,000
– –
QGENF
74
DELISTED
QIAGEN NV
QGENF
$2.53M 0.39%
91,500
+11,500
+14% +$318K
CLDX icon
75
Celldex Therapeutics
CLDX
$3.22B
$2.51M 0.38%
10,667
– –
1 2
3
4 5

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.54% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.55% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q4 2015 Portfolio in Review

As of Q4 2015, Bellevue Asset Management (Switzerland) held 140 positions worth $656M, up 7% from $613M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Asset Management (Switzerland)'s Q4 2015 filing shows 7 new, 40 increased, 26 reduced and 13 closed positions. Its largest new stake was Lannett Company, Inc.: 26,870 shares worth $4.31M. The largest sale was Allergan plc, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Asset Management (Switzerland)'s largest Q4 2015 buy was Lannett Company, Inc.: 26,870 shares worth $4.31M.
  • Bellevue Asset Management (Switzerland) added most to Cardinal Health in Q4 2015, an estimated $7.77M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q4 2015 reduction was Kite Pharma, Inc., cutting an estimated $7.43M.
  • Bellevue Asset Management (Switzerland) fully exited Allergan plc in Q4 2015, selling an estimated $13.6M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 31% of its $656M portfolio in Q4 2015.
  • Bellevue Asset Management (Switzerland) opened 7 new positions and closed 13 in Q4 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value rose 7% quarter-over-quarter to $656M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.